• Bispecific Antibodies: Mechanism Overview & Development Challenges
    By Published On: November 22, 2024Categories:

    Traditional antibody therapies are designed to target a single antigen. However, many complex diseases are driven by multiple factors, so inhibiting a single target may fail to achieve significant efficacy.

  • Balancing Innovation and Risk Management in R&D
    By Published On: November 22, 2024Categories:

    Biotech, CDMOs, and big pharma must collaborate strategically to balance innovation with risk management in R&D.

  • 8 Key Insights for Finding the Right CDMO
    By Published On: November 22, 2024Categories:

    The digital transformation of CDMO selection is revolutionizing how partnerships are formed. A digitized RFP (Request for Proposal) process can streamline workflows, improve transparency, and ultimately speed up decision-making.

  • Blueprint for Proposal Reviews (RFPs & RFQs): Biotech & CDMO Strategies in the Digital Competitive Era
    By Published On: October 15, 2024Categories:

    The Request for Proposal (RFP) process is not just a formality, but a crucial step in establishing effective collaborations between biotechs and Contract Development and Manufacturing Organizations (CDMOs).

  • Transforming CDMOs through Innovation, Customer-Centricity, and Service Excellence
    By Published On: October 10, 2024Categories:

    CDMOs play a pivotal role in accelerating drug development and manufacturing processes.

  • Biotech Innovation: Guiding points on Fast-to-Clinic / Fast-to-Market Strategies for Biotech & CDMOs
    By Published On: October 10, 2024Categories:

    In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs.

  • Antibody Drug Conjugates (ADCs) Guiding points on Seamlessly Integrating Development, Manufacturing, Safety, and Supply Chain Excellence
    By Published On: October 10, 2024Categories:

    Antibody-drug conjugates (ADCs) are pioneering biologics that merge antibodies' specificity with small molecules' potency.

  • Driving Biotech Innovation
    By Published On: September 14, 2024Categories:

    This article explores biotech's fast-to-clinic/market strategy, focusing on the role of CDMOs.

  • ADCs and their Drug Development Process
    By Published On: September 14, 2024Categories:

    One of the fastest-growing modalities in the pharmaceutical industry, antibody-drug conjugates (ADCs), combines a targeted antibody with a cytotoxic payload to offer numerous therapeutic benefits.

  • Fast-to-Clinic, Fast-to-Market in Biotech Innovation: Optimizing Chemistry Manufacturing & Controls (CMC) Excellence for Clinical and Commercial Success 2024
    By Published On: July 24, 2024Categories:

    In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market.